Cargando…

Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS

CONTEXT: Metabolic dysfunction–associated fatty liver disease (MAFLD) is highly prevalent among patients with type 2 diabetes mellitus (T2DM); however, there is still no approved pharmacological treatment. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have been suggested to beneficially modify...

Descripción completa

Detalles Bibliográficos
Autores principales:	Borisov, Angel N, Kutz, Alexander, Christ, Emanuel R, Heim, Markus H, Ebrahimi, Fahim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Clinical Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584001/ https://www.ncbi.nlm.nih.gov/pubmed/37149821 http://dx.doi.org/10.1210/clinem/dgad249

Ejemplares similares

Canagliflozin and Cardiovascular disease- results of the CANVAS trial
por: Shah, Syed Raza, et al.
Publicado: (2018)

Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program
por: Weir, Matthew R, et al.
Publicado: (2020)

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program
por: Rådholm, Karin, et al.
Publicado: (2018)

Canagliflozin and Stroke in Type 2 Diabetes Mellitus: Results From the Randomized CANVAS Program Trials
por: Zhou, Zien, et al.
Publicado: (2019)

The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus
por: Carbone, Salvatore, et al.
Publicado: (2019)

Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program
por: Matthews, David R., et al.
Publicado: (2019)

Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program
por: Matthews, David R., et al.
Publicado: (2020)

Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program
por: Wang, Katherine M., et al.
Publicado: (2021)

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
por: Mahaffey, Kenneth W., et al.
Publicado: (2018)

Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program
por: Zhou, Zien, et al.
Publicado: (2019)

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data From the CANVAS Program
por: Neuen, Brendon L., et al.
Publicado: (2018)

Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS‐R trials
por: Neal, Bruce, et al.
Publicado: (2017)

Lifetime risk and health-care burden of diabetic ketoacidosis: A population-based study
por: Ebrahimi, Fahim, et al.
Publicado: (2022)

PromarkerD Predicts Renal Function Decline in Type 2 Diabetes in the Canagliflozin Cardiovascular Assessment Study (CANVAS)
por: Peters, Kirsten E., et al.
Publicado: (2020)

Association Between Circulating GDF‐15 and Cardio‐Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial
por: Sen, Taha, et al.
Publicado: (2021)

Canva
por: Gehred, Alison Paige
Publicado: (2020)

Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program
por: Ohkuma, Toshiaki, et al.
Publicado: (2020)

Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program
por: Yu, Jie, et al.
Publicado: (2021)

Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial
por: Sen, Taha, et al.
Publicado: (2021)

Endotrophin is a risk marker of complications in CANagliflozin cardioVascular Assessment Study (CANVAS): a randomized controlled trial
por: Rasmussen, Daniel Guldager Kring, et al.
Publicado: (2022)

Association of adrenal insufficiency with patient-oriented health-care outcomes in adult medical inpatients
por: Ebrahimi, Fahim, et al.
Publicado: (2019)

Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS‐R): A randomized, placebo‐controlled trial
por: Neal, Bruce, et al.
Publicado: (2017)

Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials
por: Fletcher, Robert A., et al.
Publicado: (2023)

Safety of parathyroidectomy in older vs. younger patients with primary hyperparathyroidism
por: Mueller, Marlena, et al.
Publicado: (2021)

HTML5 canvas
por: Fulton, Steve, et al.
Publicado: (2013)

HTML5 Canvas
por: Fulton, Steve, et al.
Publicado: (2011)

CANVAS is an Oligosymptomatic Disease
por: Ruiz-Fernández, Emilio, et al.
Publicado: (2022)

Mechanisms of action of the sodium‐glucose cotransporter‐2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial
por: Sen, Taha, et al.
Publicado: (2022)

Canagliflozin Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism and Inhibiting Inflammation through Induction of Autophagy
por: Xu, Zhipeng, et al.
Publicado: (2022)

Foundation HTML5 canvas
por: Hawkes, Rob
Publicado: (2011)

HTML5 Canvas Cookbook
por: Rowell, Eric
Publicado: (2011)

Scientists as seen by children—on canvas
por: CERN Bulletin
Publicado: (2010)

Diversity and Metabolic Activity of Fungi Causing Biodeterioration of Canvas Paintings
por: Văcar, Cristina Lorena, et al.
Publicado: (2022)

Risk of Adverse Clinical Outcomes in Hyponatremic Adult Patients Hospitalized for Acute Medical Conditions: A Population-Based Cohort Study
por: Kutz, Alexander, et al.
Publicado: (2020)

Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study
por: Itani, Toshio, et al.
Publicado: (2018)

Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program
por: Ferrannini, Giulia, et al.
Publicado: (2022)

Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis
por: Sinclair, Alan J., et al.
Publicado: (2016)

CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice
por: Woo, Vincent, et al.
Publicado: (2018)

Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
por: Triplitt, Curtis, et al.
Publicado: (2015)

No obesity paradox in patients with community-acquired pneumonia – secondary analysis of a randomized controlled trial
por: Borisov, Angel N., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6dgl8nkgd0jfus9bjv2s8lkbp0